For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Eli Lilly and CompanyLLY US · Health Care · USD Current price$1351.12as of Nov 20, 2026 Summary
Analyst consensusStrong Buy 5Buy 20Hold 4Sell 1Strong Sell 129 analysts 3-year price (USD)Factor profileMulti-factor score 97 / 100 Market data
Business descriptionEli Lilly and Company (LLY) is a leading global biopharmaceutical company dedicated to discovering, developing, and marketing innovative medicines in areas including diabetes, obesity, immunology, oncology, and neurological disorders. Competitive moatEli Lilly commands an exceptional competitive moat anchored by its dominant leadership in incretin-based therapies (Mounjaro and Zepbound) and its rapidly expanding next-generation obesity and metabolic pipeline. Supported by massive manufacturing capacity investments and strong intellectual property estates, Lilly continues to outpace peers through aggressive internal R&D and targeted external M&A. Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Oct 11, 2026
Current price: $1351.12 · Nov 20, 2026· USD
CFRA Ratingbuy12-Mo Target: USD 1,395.00
TBI Multi Score97
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: LLYBusiness description
Eli Lilly and Company (LLY) is a leading global biopharmaceutical company dedicated to discovering, developing, and marketing innovative medicines in areas including diabetes, obesity, immunology, oncology, and neurological disorders.
Competitive moat
Eli Lilly commands an exceptional competitive moat anchored by its dominant leadership in incretin-based therapies (Mounjaro and Zepbound) and its rapidly expanding next-generation obesity and metabolic pipeline. Supported by massive manufacturing capacity investments and strong intellectual property estates, Lilly continues to outpace peers through aggressive internal R&D and targeted external M&A.
Recent developments
- Oral GLP-1 Approval & Launch (April 2026): FDA approved once-daily oral GLP-1 receptor agonist orforglipron (Foundayo) for chronic weight management in adults with obesity. Commercialized via LillyDirect and retail pharmacies, offering low-cost entry points.
- Acquisitions & Pipeline Diversification: Announced strategic acquisitions including Kelonia Therapeutics (in vivo CAR-T iGPS platform, ~$7B), Orna Therapeutics (circular RNA platform, ~$1B), Curevo, and LimmaTech to expand into next-gen genetic medicines, vaccines, and oncology.
- U.S. Government Access Agreement: Entered a landmark agreement in late 2025/early 2026 providing Medicare copay benefits for Zepbound and LillyDirect discounts, securing tariff grace periods and domestic manufacturing support.
- Manufacturing Footprint Expansion: Announced major domestic API and manufacturing site investments (such as a $6.5B project in Texas) to support surging global demand for GLP-1 treatments.
Investment risks / red flags
- Slower-than-expected prescription growth or reimbursement headwinds.
- Clinical trial setbacks or lower-than-expected efficacy in pipeline candidates.
- Intense competition in the obesity and metabolic space.
Market Data
Source: mkts.io · Nov 20, 2026, 04:01 UTC
Key Metrics
P/E (TTM)43.85
P/E (Fwd)26.56
Dividend0.50%
Beta0.39
52W High$1475.25
52W Low$850.51
Analyst Consensus
5
20
4
Strong Buy5Buy20Hold4Sell1Strong Sell129 analysts
Consensus Target$1470.06
+8.8% upside
Calendar Events
Next EarningsOct 29, 2026
Ex-DividendNov 13, 2026
Dividend DateDec 10, 2026
Financials
Revenue$86.46B
Rev Growth38.60%
Earnings Growth16.30%
Gross Margin83.63%
Op Margin51.25%
Profit Margin31.90%
EBITDA$46.49B
ROA21.06%
ROE86.02%
Rev/Share$96.75
Total Cash$4.89B
Total Debt$49.50B
D/E Ratio122.92
Free Cash Flow$9.34B
Op Cash Flow$30.65B
Current Ratio1.39
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 11.26 | $24.73B |
| +1q | 10.94 | $23.55B |
| 0y | 35.48 | $91.68B |
| +1y | 50.87 | $106.58B |
Earnings
Quarterly EPS
4Q2025
Est: 6.917.54Beat
1Q2026
Est: 6.798.55Beat
2Q2026
Est: 6.588.38Beat
3Q2026
Est: 6.357.48Beat
Annual
2022
Rev $28.54BEarn $6.24B
2023
Rev $34.12BEarn $5.24B
2024
Rev $45.04BEarn $10.59B
2025
Rev $65.18BEarn $20.64B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Nov 9, 2026 | Jefferies | main | Buy |
| Nov 2, 2026 | Cantor Fitzgerald | main | Overweight |
| Oct 31, 2026 | UBS | main | Buy |
| Oct 30, 2026 | JP Morgan | main | Overweight |
| Oct 30, 2026 | Citigroup | main | Buy |
| Oct 30, 2026 | Scotiabank | main | Sector Outperform |
